BME100 f2013:W1200 Group1 L1

BME 100 Fall 2013	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Jeff Miles Name: Chloe Kwon Name: Casey Weinstein Name: Nima Afzalian Name: Mario Gonzalez Name: Jacqueline Pauly LAB 1 WRITE-UP Independent and Dependent Variables Independent variable: the amount of lipopolysaccharide (LPS) given to test subjects Dependent variable: the amount of inflammatory protein (Inflammotin) in the blood samples of test subjects Experimental Design Groups The experiment will contain eleven groups, each given a different dose of LPS. Number of subjects per group There will be 100 people per group. Each group of 100 people will be given a different dosage of LPS through a pill. Group 1 will be the control group and will not take any LPS. Each group will take more LPS in increments of 3 mg, ranging from doses of 0mg-30mg. The subjects will take one dose per day for three months. At the end of every week, the test subjects' blood will be tested using ELISA for increased/decreased inflammation protein levels. The data from the test subjects in each of the eleven groups will be averaged and compared at the end of the three months. The goal by the end of the experiment is to determine the lowest dosage of lipopolysaccharide (LPS) in order to increase the inflammatory protein (Inflammotin) in the elderly. Subject Selection Subjects will be chosen and grouped by age. Within each major group consisting of 100 people, 25 people will be aged 40-49 years, 25 people will be aged 50-59 years, 25 people will be aged 60-69 years, and 25 people will be aged 70-79 years. Additionally, each age category within each group will be roughly 50% male and 50% female. Test subjects will be chosen from all different locations across the US; race/ethnicity will not be a factor when choosing test subjects. Sources of Error and Bias The experimental budget is limited, which affects the sample size and selection and can cause inaccurate results. The test subjects will not be screened for pre-existing health conditions, which may affect the overall response to the medication. The test subjects may be on different types of medication which could cause a counter effect on the LPS. In order to better control this, test subjects will be asked to limit the number of additional drugs and medications throughout the experiment. The experimental design is not a double-blind procedure. This may cause the distributor and the test subjects to be biased on the decisions of whether the LPS is effective or not. The control group should be given a sugar pill so that they will not know if they are being dossed or not. The location, ethnicity, and race of the test subjects can affect the response to the LPS as well. <------Mario and Nima contributed and helped Jacqueline